Author Login IJIRT Partner Network (IPN) Login

EVALUATION OF EMERGING IN-VITRO ASSAYS IN CERVICAL CANCER

  • Unique Paper ID: 154657
  • Volume: 8
  • Issue: 12
  • PageNo: 47-52
  • Abstract:
  • Cervical cancer is one of the most common types of gynaecological cancer in women. It's also one of the most frequent cancers in women, and it's one of the few that may be detected and treated entirely at the precancerous stage. Cervical cancer is caused mostly by sexually transmitted diseases (STDs), as well as the Human Papillomavirus (HPV), particularly HPV-16 and HPV-18. In India, it is still a big public health issue for women. Cervical cancer strikes women between the ages of 55 and 59, and a large percentage of those diagnosed are in advanced stages of the disease. Cervical cancer vaccinations include prophylactic vaccines against HPV-16 and 18 therapeutic v. Premature sexual activity, teen pregnancy, family history, and oral contraceptives are all epidermal risk factors. This page discusses the history of cervical cancer, histological types, risk factors, prevention, therapy, and drugs approved to prevent cervical cancer. Squamous cell carcinoma is the most frequent kind of cervical cancer. Only persons who have never been infected with HPV benefit from the vaccines.
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 8
  • Issue: 12
  • PageNo: 47-52

EVALUATION OF EMERGING IN-VITRO ASSAYS IN CERVICAL CANCER

Related Articles

Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry